Physician profile
Michelle Marie Holloway
NPI 1235166364
$47,478.20
in general payments reported to CMS, 2019-2025
16 companies · $4,894 in 2025
The $4,894 reported for 2025 was more than what 97% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $216 · 2020: $191 · 2021: $59.04 · 2022: $270 · 2023: $979 · 2024: $41K · 2025: $4,894.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $37K · Travel and Lodging: $5,872 · Food and Beverage: $3,443 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $37,419.25 |
| Travel and Lodging | $5,871.79 |
| Food and Beverage | $3,443.30 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Pharmaceuticals, INC. | $39,975.57 | 2024 | Xelstrym |
| Noven Therapeutics, LLC | $4,651.73 | 2023-2025 | Xelstrym, Secuado |
| Otsuka America Pharmaceutical, INC. | $1,150.07 | 2019-2025 | Rexulti, Abilify Maintena |
| Abbvie INC. | $446.15 | 2022-2025 | |
| Supernus Pharmaceuticals, INC. | $228.86 | 2023-2024 | Qelbree, Qelbree |
| Bausch Health US, LLC | $202.58 | 2023-2025 | Aplenzin, Wellbutrin |
| Corium, LLC | $200.22 | 2022-2023 | Azstarys |
| Janssen Pharmaceuticals, INC | $192.11 | 2019-2024 | Spravato |
| Axsome Therapeutics, INC. | $101.17 | 2023 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $95.37 | 2020-2024 | Austedo Xr |
| Ironshore Pharmaceuticals INC. | $74.57 | 2023-2024 | Jornay Pm |
| Neurocrine Biosciences, INC. | $73.31 | 2023-2024 | Ingrezza |
| Collegium Pharmaceutical, INC. | $24.76 | 2025 | Jornay Pm |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $23.50 | 2024 | Caplyta |
| Sunovion Pharmaceuticals INC. | $21.22 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $17.01 | 2025 | Dyanavel Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Holloway listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.